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Abstract: Among parasitic diseases, morbidity and
mortality caused by leishmaniasis are surpassed only by
malaria and lymphatic filariasis. However, estimation of
the leishmaniasis disease burden is challenging, due to
clinical and epidemiological diversity, marked geographic
clustering, and lack of reliable data on incidence, duration,
and impact of the various disease syndromes. Non-health
effects such as impoverishment, disfigurement, and
stigma add to the burden, and introduce further
complexities. Leishmaniasis occurs globally, but has
disproportionate impact in the Horn of Africa, South Asia
and Brazil (for visceral leishmaniasis), and Latin America,
Central Asia, and southwestern Asia (for cutaneous
leishmaniasis). Disease characteristics and challenges for
control are reviewed for each of these foci. We
recommend review of reliable secondary data sources
and collection of baseline active survey data to improve
current disease burden estimates, plus the improvement
or establishment of effective surveillance systems to
monitor the impact of control efforts.
Introduction
Leishmaniasis comprises a complex of vector-borne diseases,
caused by more than 20 species of the protozoan genus Leishmania,
and ranging from localized skin ulcers to lethal systemic disease
[1,2]. Leishmaniasis is classified as one of the ‘‘most neglected
diseases’’ [3], based on the limited resources invested in diagnosis,
treatment, and control, and its strong association with poverty [4].
Published disease burden estimates place leishmaniasis second in
mortality and fourth in morbidity among all tropical diseases [5].
The tools exist to achieve much better control of leishmaniasis.
Research efforts over the past decade have augmented the range of
field-applicable diagnostic tools and effective antileishmanial drugs
available, especially for visceral leishmaniasis [6]. Appropriate use of
vector control interventions, such as insecticide-treated nets and
indoor residual spraying, would greatly reduce incidence [7–10].
Nevertheless, leishmaniasis control efforts have been impeded by the
lack of a simple strategy, such as a vaccine. With the impetus of a
‘‘rapid impact package’’ for the small group of neglected diseases
amenable to control through mass drug administration [11],
leishmaniasis is in danger of becoming an even more neglected
disease.
The characteristics that complicate large-scale interventions
against leishmaniasis also present a challenge to preparing realistic
disease burden estimates. Leishmaniasis incidence is geographi-
cally heterogeneous: while the rate across a region may appear
low, focal areas are intensely affected [9,12]. Leishmaniasis causes
highly varied clinical syndromes, each presenting distinct diag-
nostic challenges, most requiring prolonged, expensive drug
therapy, and each contributing differently to disease burden.
Interactions with malnutrition and HIV alter the clinical course,
and complicate therapeutic strategies [13,14]. Epidemiologic
features and the choice of appropriate control measures vary with
parasite species and geographic area, depending on reservoir hosts
and biological aspects of the vectors [2]. Finally, the impact on
patients and their families does not end with health effects, but
includes the social and psychological stigma of visible lesions and
disfigurement, and significant economic losses [4]. This article
reviews the major clinical features and epidemiology of leishman-
iasis, and describes aspects of the disease burden in the most
important foci.
Clinical Features
The most common syndrome is localized cutaneous leishman-
iasis (CL), most frequently caused by Leishmania major and L. tropica
in the Old World, and L. braziliensis, L. mexicana, and related species
in the New World [1,15]. Spontaneous healing is the rule, but
requires months to years, and varies by species [15]. Mucosal
leishmaniasis (ML) usually occurs months or years after healing of
primary CL, most commonly due to L. braziliensis, and can cause
destruction of the nasal septum, palate, and other mucosal
structures, leading to devastating facial mutilation and, rarely,
death from airway involvement [16]. Other complicated forms
include disseminated cutaneous leishmaniasis (DCL), diffuse
nodular non-ulcerating disease, and leishmaniasis recidivans,
localized slowly progressive non-healing lesions. Both are rare,
difficult to treat, and can be severe.
Visceral leishmaniasis (VL) is usually caused by L. donovani and L.
infantum, and is characterized by progressive fever, weight loss,
splenomegaly, hepatomegaly, hypergammaglobulinemia, and pan-
cytopenia [1]. Complications include immunosuppression and
secondary bacterial infections, hemorrhage, anemia, and, when
kala-azar occurs during pregnancy, fetal wastage or congenital
leishmaniasis [17]. Kala-azar is lethal in nearly all untreated cases
[18,19]. Even intreatedpatients, case-fatality rates areoften 10%or
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associated with increased risk of mortality [9,20,21].
Post-kala-azar dermal leishmaniasis (PKDL) is a chronic rash
seen in apparently cured kala-azar patients in South Asia and the
Horn of Africa [22,23]. PKDL patients present with erythematous
or hypopigmented macules, sometimes progressing to plaques or
nodules. In Sudan, PKDL is reported to resolve without treatment
in most mild cases, while the condition is said to require universal
treatment in South Asia [23]. However, recent data from
Bangladesh suggest that a proportion of PKDL cases self-resolve
in South Asia as well [24]. Up to 60% of kala-azar patients
develop PKDL in Sudan [23]; in South Asia, prospective data are
lacking, but the cumulative incidence is currently thought to be in
the range of 10%–20% [22,24].
HIV–leishmaniasis co-infection poses a growing problem in
developing countries [13]. In HIV-infected individuals without
severe immunosuppression, manifestations are similar to those in
immunocompetent persons. Among those with CD4+ T lympho-
cyte counts ,200 cells/mL, manifestations of leishmaniasis may be
more severe or affect unusual sites such as the gastrointestinal tract
[25]. In the absence of highly active antiretroviral therapy
(HAART), the relapse rate after treatment approaches 100% [13].
Epidemiology and Ecology
The leishmaniases are transmitted to humans in sylvatic,
domestic, and peridomestic cycles ranging from cities to deserts
and rain forests on every continent except Australia and
Antarctica (Table 1). Nevertheless, the human disease burden is
relatively concentrated; 90% of VL cases occur in India,
Bangladesh, Nepal, Sudan, Ethiopia, and Brazil, while 90% of
CL occurs in Afghanistan, Algeria, Iran, Saudi Arabia, Syria,
Brazil, Colombia, Peru, and Bolivia [26,27]. The distribution is
dynamic: Colombia and Ethiopia have recently joined this list, and
Pakistan currently faces a large epidemic of CL in Baluchistan and
Sindh (World Health Organization [WHO], unpublished data).
Climate change and other environmental changes have the
potential to expand the geographic range of the vectors and
leishmaniasis transmission in the future [28].
In sylvatic cycles, such as those in New World rain forests and
the deserts of Central Asia, animal reservoir hosts can maintain
enzootic transmission indefinitely without human disease. Spo-
radic or epidemic leishmaniasis occurs when humans enter the
sylvatic habitat for economic or military purposes, or when human
habitation encroaches on the sylvatic setting. In domestic cycles,
humans or dogs form the predominant or sole infection reservoir.
The foci that account for the largest number of human cases, for
example, VL in South Asia and CL in Afghanistan, usually reflect
anthroponotic transmission [1,29]. In anthroponotic VL foci, the
reservoir includes humans with untreated kala-azar [9], but PKDL
patients may maintain the infection between kala-azar epidemics
[30]. Up to half the population in highly affected foci may have
asymptomatic leishmanial infection; the contribution of such
individuals to transmission is presumed to be less than for active
kala-azar, but has never been quantified [31,32].
Disease Burden Estimates
The most objective measures of disease burden are incidence,
prevalence, and mortality. Several derived measures incorporate
indicators of disease severity, disability, and/or quality of life into
composite outcomes that can be compared across diseases [33].
Currently, the most widely used measure is ‘‘disability-adjusted life
years lost’’ (DALY) [5,33]. Leishmaniasis DALY estimates are
based on (1) figures assumed for regional incidence and
prevalence, (2) assumed case-fatality rates, and (3) assigned
disability weights for CL and VL [33]. For leishmaniasis, there
are major uncertainties and sparse documentation for the
assumptions underlying all three of these components. The
empirical basis and derivation of global and regional leishmaniasis
incidence and prevalence figures have not been documented since
1991 [34,35]. Passive surveillance is generally given as their basis,
but leishmaniasis is notifiable in only 33 of 88 endemic countries
[26]. Substantial underreporting is widely acknowledged [26], but
its magnitude has rarely been measured, and in studies, has varied
from 2-fold to 40-fold [36–38]. In many countries, the majority of
leishmaniasis cases are treated by non-governmental organizations
or in the private sector, but these cases are not usually included in
surveillance data, exacerbating underreporting. Underreporting is
likely to vary greatly, not only among countries and depending on
the clinical syndrome, but even between localities in the same
district, based on distance to health care, availability of private
providers and of antileishmanial drugs, the presence of research
groups, and local awareness of the disease. Differential underre-
porting is labor-intensive to document, and precludes valid
generalization of incidence and reporting rates presented in
research studies. Underreporting of deaths is even more
pronounced. One study from Sudan estimates that 91% of all
kala-azar deaths went unrecognized [39], while data from a
village-based study in India suggest that as many as 20% of VL
patients, disproportionately poor and female, died before their
disease was recognized [40]. The origin and derivation of the
disability weights assigned for VL and CL are not documented
[33]. In the absence of data to address these shortcomings, this
article will describe the characteristics of leishmaniasis that
contribute to the disease burden in the most important foci, and
aspects that should be taken into account in future attempts to
quantify its impact and monitor control programs.
Horn of Africa
In global estimates, the Horn of Africa (Sudan, Ethiopia,
Kenya, Somalia) accounts for the second largest number of annual
VL cases, after South Asia [41]. Transmission dynamics are
complex, involving parasites identified by standard laboratory
techniques as both L. donovani and L. infantum [42,43], and two
distinct ecological settings, semi-arid regions in the north where
Phlebotomus orientalis is the major vector, and the savanna and forest
areas in the south where P. martini and P. celiae are found in
association with Macrotermes termite mounds [44,45]. Investigators
have suggested that VL originated in the Sudan, based on the
ancestral position of the circulating parasites in genetic analyses
[46,47]. While sporadic sylvatic VL transmission is well recognized
[48], sustained peridomestic and domestic cycles in villages, and
explosive epidemics affecting populations displaced in recent wars,
account for the bulk of human cases [42,43,49]. In zoonotic foci,
both sylvatic rodents [50] and domestic dogs [51] may act as
infection reservoirs, but large outbreaks are usually thought to
involve anthroponotic transmission.
The association of leishmaniasis epidemics with war, ecological
disasters, famine, and forced migration is most marked in the Horn
of Africa. During the long civil war in Sudan, hundreds of thousands
of VL cases occurred, causing the deaths of 30%–60% of the
population in many communities [49]. The high attack rates among
all ages and very high mortality rates were due to the confluence of
displaced populations with no immunity, high rates of malnutrition,
and lack of treatment access [20,49,52,53]. Malnutrition is a major
determinant of both progression to and severity of clinically manifest
VL [14,54,55], and greatly increases the case-fatality rate [20].
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www.plosntds.org 3 October 2008 | Volume 2 | Issue 10 | e313Poverty, poor housing, crowded conditions, lack of personal
protective modalities such as bed nets, environmental degradation,
and collapseofhealth caresystemsintensifythe spread andimpactof
VL in these settings. Seasonal labor movements may also spread the
disease: introduction of the parasite by returning migrant farm
workers is thought to have initiated an outbreak of VL in north
central Ethiopia, an area not previously endemic [42]. VL epidemics
with similar underlying causes have occurred recently in Somalia
[56,57] and Kenya [58,59]. Cutaneous leishmaniasis may also
accompany population displacements, for example, in Kurdish
refugee camps in north Syria, Sudanese refugee camps in Chad, and
among returned refugees in Afghanistan [60–62] (and WHO,
unpublished data).
HIV–VL co-infection further complicates the picture by
accelerating the progression of both diseases and making VL
virtually untreatable in the absence of HAART [13,63]. The
Tigray region, bordering Eritrea and Sudan, has high rates of both
HIV and VL among the many soldiers and seasonal workers;
seasonal workers often sleep under Acacia trees where sand flies
rest, increasing risk of VL [44]. In recent studies in Tigray, 20%–
30% of VL patients were co-infected with HIV; co-infection was
associated with a 5-fold increase in mortality within 6 months,
lower clinical cure rates with frequent relapses, and increased side
effects from antimonial drugs [64,65]. HIV–VL co-infected
patients are highly infectious to sand flies [66], and have the
potential to spread resistant parasite clones, posing an additional
threat to control programs.
South Asia (India, Nepal, and Bangladesh)
If Sudan is the original home of VL, South Asia is its domestic
heartland. In the 19th century, devastating outbreaks of a chronic
progressive febrile illness with cachexia, hepatosplenomegaly, and
high fatality rates were reported in Bengal and Assam, and
retrospectively thought to be the first recorded VL epidemics [19].
In 1903, Leishman and Donovan first described the organism that
now bears their names in patients infected in India [67,68].
Today, South Asia is estimated to account for 60% of the global
VL disease burden [41], with a sustained endemic focus stretching
from Bihar and Bengal in northeastern India, across the border
into southeastern Nepal, and to the east into central and western
Bangladesh. The parasite in South Asia is transmitted by
Phlebotomus argentipes, an endophilic vector that rests in human
and animal dwellings in densely populated agricultural villages.
Kala-azar incidence fell substantially during the indoor residual
insecticide spray campaigns of the malaria eradication effort of the
1950s and 1960s, but the disease returned in the 1970s and
transmission has been sustained since then [69,70].
Superimposed on this poorly controlled endemic picture, India
has experienced recurrent epidemics in the 1970s and early 1990s,
and Bangladesh has seen a progressive increase in VL incidence
from the mid-1990s to the present that shows no signs of abating
[12,69,70]. In most areas, there is a fairly stable incidence of two
to three kala-azar cases per 1,000 population per year [36], but
with localized foci of intense transmission and 10-fold higher
annual incidence rates [71]. Transmission hot spots may be
sustained for several years, but then appear to burn out, limited by
saturation of the susceptible population [9]; increases in incidence
are then seen in neighboring areas. Several years after peaks in
kala-azar incidence, the same communities may see large numbers
of PKDL cases, in an echo of the original kala-azar outbreak [24].
PKDL patients remain infectious for years to decades [30], and
require prolonged antileishmanial treatment, up to 120 days [72],
representing a significant challenge to health care systems in which
kala-azar patients experience difficulty obtaining much shorter
treatment courses [73].
Facility-based studies from South Asia often report higher kala-
azar incidence in males than females [74]; community-based data
suggest that there is little difference in incidence by sex, but
substantial differences in care-seeking behavior [40,71]. In South
Asia, the mean duration of kala-azar illness before treatment is 3–5
months; on average, women are ill longer than men, and are more
likely to die from the disease [8,40,71,75,76]. In one highly affected
village in Bangladesh, reproductive-age women were three times as
likely to die from kala-azar compared to men or children; kala-azar
accounted for 23% of all deaths, and 80% of those in adult women
[71,73]. Qualitative data from the same village suggest that women
experience higher barriers to seeking care [71,75]; poorer baseline
iron, zinc, and vitamin A status may also play a role in higher
morbidity and mortality among women [31].
Although the morbidity and mortality caused by kala-azar and
PKDL are substantial, the impact on affected individuals and their
families is compounded by the expense and time involved in
gaining access to appropriate diagnosis and treatment. The cost of
caring for a patient with kala-azar in South Asia (US$80–US$120)
approaches or surpasses the annual per capita income, and
substantial additional income is lost by patients and family
members unable to work [73,77–79]. In Bihar and southern
Nepal, costs have been multiplied many-fold by resistance to
antimonial drugs and the imperative to use more expensive
alternatives [6,80,81]. The upsurge in PKDL cases now seen in
Bangladesh will also increase difficulties for patients and their
families; even if the drug is supplied gratis, the 120-day parenteral
treatment course entails many other costs, such as payments for
daily injections and transport to the health care facility, and is
associated with much lost work time. Anecdotally, a number of
PKDL patients died suddenly during treatment, consistent with
antimonial cardiotoxicity [24].
Visceral Leishmaniasis in Brazil and Other Parts of
Latin America
From Mexico to Argentina, L. infantum (synonym L. chagasi)i s
transmitted from dogs to humans primarily by Lutzomyia longipalpis,
a vector well adapted to the domestic and peridomestic
environment. Brazil accounts for 90% of reported VL cases in
the Americas, and is the third most important VL focus globally
[82]; unlike other major VL foci, case reporting is mandatory in
Brazil, and surveillance data are more complete. However,
American VL is in the midst of dramatic changes in transmission
patterns and a marked geographic expansion, superseding
previous estimates of disease burden.
VL traditionally occurred in poor rural areas in dry northeast
Brazil. In the early 1980s, the first of a series of urban epidemics
occurred in Teresina [83], followed by outbreaks in Sa ˜o Luis,
Natal, Fortaleza, and elsewhere [84]. Periurban VL outbreaks
followed the massive migration of rural populations to the
periphery of large cities because of drought, loss of farmland,
and poverty [85]. In rapidly growing, densely settled favelas,
environmental degradation, precarious living conditions, inade-
quate sewage and garbage disposal, and close contact with dogs
and other domestic animals promote vector proliferation and
disease transmission [86,87]. The reported VL incidence in Brazil
doubled from a mean of 1,500 cases per year in the 1980s to more
than 3,000 per year from 2000 to 2005; the disease now occurs in
urban, periurban, and rural areas as far south as the states of Sa ˜o
Paulo and Mato Grosso do Sul, in addition to the traditionally
endemic northeast [82]. Children, particularly those with
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fatality rate approaches 10% in some centers, despite good
availability of treatment [88]. Although the geographic ranges of
HIV infection and VL overlap and continue to expand, the
number of reported cases of VL with AIDS (176 from 2001–2005)
has been fewer than expected, perhaps because of free, universal
distribution of antiretroviral drugs by the Brazilian government,
and some degree of underrecognition by clinicians [89]. An
additional 315 cases of VL–HIV co-infection without AIDS are
estimated to have occurred during that period [90].
Control of zoonotic VL has proved difficult. From 1999–2005,
human VL incidence remained high despite aggressive control
efforts centered on culling of infected dogs and insecticide
application [91]. The failure of the previous control strategy
[92], and demonstration of canine infections and subclinical
human infections in areas not previously endemic [93], have led to
a revised national strategy that includes surveillance and
preventive measures in areas considered at risk for infection, even
in the absence of clinical cases [82].
Cutaneous Leishmaniasis in the Americas
At least 12 different Leishmania species cause American CL, and
the disease occurs in every country from the United States to
Argentina, except Uruguay and Chile. Until recently, Brazil and
Peru reported the first and second highest incidence in the
Americas [15,26]. However, with more than 15,000 reported cases
in 2005 and 2006, Colombia now ranks second after Brazil
(.30,000 per year); thousands of cases occur in Peru (,6,500 per
year) and elsewhere in Latin America as well [15,89,94,95]. The
epidemiology of CL in the Americas is complex, with intra- and
inter-specific variation in transmission cycles, reservoir hosts, sand
fly vectors, clinical manifestations, and response to therapy [96].
Studies often demonstrate five or more species causing lesions in
the same area [97–99].
There has been an expansion both in the geographic range and
risk factors for CL transmission. In the past, American CL was
predominantly an occupational disease, related to activities in
forests and other enzootic areas. Occupational exposures remain
important, as demonstrated by 3,163 reported CL cases among
Colombian soldiers infected during patrols in forested areas held by
insurgents in 2004 [60]. However, widespread deforestation has led
to a rapid increase in cases, rather than a decrease as once
predicted, and to peridomestic, periurban, and even urban
transmission [100]. For example, from 1980 to 2001, there was a
10-fold increase in CL incidence and spread to all of the states of
Brazil [63,101]. Outbreaks in newly arrived, immunologically naive
immigrants have occurred in new settlements in previously forested
areas [102] and among economic migrants in the lowlands of
Bolivia [103]. A contrasting report documents new occurrence of L.
amazonensis infection in a settled population in a sub-Andean region
of Bolivia at 1,450–2,100 meters above sea level, presumably
reflecting spread from its traditional lowland focus [104].
CL patients face social stigma and isolation [27]. A study from
Colombia reported that cutaneous ulcers in a woman can be the
pretext for spousal abandonment [105]. Among Ecuadorian
villagers, almost 70% of persons believed that CL interfered with
the capacity to work, while 82% stated that the presence of an
ulcer or scar diminished self-esteem [106]. Participants mentioned
over 150 different treatments for CL, including potentially harmful
application of acids, gasoline, and lighted matches [106].
Disfiguring, mutilating, and occasionally life-threatening lesions
of ML have been reported in 25%, 14%, 2%, and 0.3% of persons
with L. braziliensis infections in Bolivia, Peru, Colombia, and
Venezuela, respectively [107]. Diffuse cutaneous leishmaniasis,
like ML, does not heal spontaneously and is difficult to treat;
although rare, this syndrome can occur in persons with L.
amazonensis or L. mexicana infections, or co-infection with HIV and
other species of Leishmania [101]. The nodular lesions resemble
those of lepromatous leprosy, and persons with DCL can suffer
stigma similar to that associated with leprosy.
CL in the Americas is a disease of the poor; in many countries,
patients and their families shoulder the high cost of treatment, and
suffer substantial lost income. For example, in Guatemala, the cost
of treatment is about US$250, beyond the means of most rural
inhabitants [27]. The disease also causes a major financial burden
on public health systems. Treatment is provided free of charge by
the governments of Colombia, where the cost of pentavalent
antimony is approximately US$345 per person cured [108], and in
Brazil, which has spent the equivalent of US$2.5 million to treat
35,000 persons with antimonial drugs, and an additional
US$500,000 to treat 95 persons with liposomal amphotericin [27].
Anthroponotic CL in Afghanistan and
Southwestern Asia
Of the major forms of leishmaniasis, the only historically
urbanized form is anthroponotic CL due to L. tropica, as illustrated
by its vernacular names, ‘‘Baghdad boil’’, ‘‘Aleppo boil’’, ‘‘Balkh
sore’’, and others [46]. Although infections in dogs and other
animalshavebeendocumented,thediseaseischaracterizedbylarge
outbreaks in densely populated cities, especially in the setting of war
and large-scale population migration. In Syria, especially the
traditional focus in the city of Aleppo, a marked increase to more
than 15,000 cases per year was documented during the 1990s, with
only a temporary decline when insecticide spray programs were
instituted in 1991 [109]. A huge CL epidemic has occurred in
Afghanistan since 1992, with estimates of 200,000 cases in Kabul
alone [110]. The annual CL incidence in Kabul peaked at 12% in
1996, and averaged 3% per year from 1992 to 2002 [29,62]. The
association between migration and CL transmission may be more
complex than originally postulated: while migrants within Kabul
were at the highest risk of CL, possibly because of economic
disadvantage, immigrants from outside Kabul were at no higher
risk, but appeared to fuel local transmission by adding to the pool of
susceptible residents [62]. Transmission occurred within the
household, even up to second floor apartments [111], and often
resulted in facial lesions, especially in women and children [62].
Women with lesions were considered unfit to marry, have children,
or breastfeed, and children with lesions were sometimes ostracized
by playmates [112].
Conclusions and Recommendations
Current methods of assessing disease burden fail to take into
account the clinical and epidemiological diversity of leishmaniasis,
and the intense medical, social, and economic impact within
highly affected foci. Furthermore, existing passive surveillance data
are grossly inadequate to be used to make reliable estimates.
Active, rigorous assessments of the true incidence, morbidity,
mortality, current transmission patterns, and non-health effects of
leishmaniasis are urgently needed. The following steps are
recommended to achieve better estimates of current disease
burden, and establish systems to monitor the impact of control
measures:
1. Assessment of the critical needs for data by geographic focus,
and development of focus-specific strategies for filling in the
many data gaps. Leishmaniasis foci targeted for elimination or
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without reliable data, on-the-ground rapid epidemiologic
assessments may be necessary to develop an appropriate plan
for data collection. Strategies include reviews of existing data,
baseline field surveys, and establishment of surveillance
systems. More than one technique may be needed in a single
focus.
2. Reviews of reported incidence and mortality data. Potential
data sources include existing surveillance systems, hospital and
specialized treatment facility records, and past surveys. Data
analysis should be preceded by a critical assessment of data
sources, quality, and potential biases.
3. Where indicated, baseline surveys to collect empirical inci-
dence and prevalence data, with the focus on the most affected
regions, and those with planned elimination or intensified
control programs. Appropriate case definitions and techniques
to capture illness onset, severity, and duration should be
developed and tested before deployment. Surveys must be
carefully designed to avoid biases due to disease clustering,
employ valid statistical methods, ensure adequate sample size,
and, if possible, employ new mapping technologies. Specialized
sampling and analysis methods, such as adaptive sampling
[113], may be necessary to address the clustered transmission
pattern of leishmaniasis. Wherever practical, risk factor
assessments should be incorporated into baseline surveys in
order to guide control efforts and make the best use of limited
resources.
4. The data collected in rapid assessments and baseline surveys
should be used to evaluate and improve existing leishmaniasis
surveillance and reporting systems. In areas without existing
surveillance, systems should be established. Where complete
coverage is not feasible, sentinel surveillance based on carefully
selected, sustainable sites with known catchment populations
may be the best option to provide data to evaluate trends over
time [114]. Systems should be tailored to local conditions, but
should be subject to ongoing evaluation to ensure reliability
and appropriateness to monitor the impact of control
programs.
5. Studies and/or surveillance system components should be
designed to provide measures of disease impact, severity, and
duration that realistically reflect the heterogeneity of leishman-
iasis. This effort should incorporate new thinking on disease
burden assessment [115], for example, including the impact of
non-health outcomes, such as economic costs, and interaction
with malnutrition or other conditions.
6. The data resulting from the above efforts should be
incorporated into a more precise assessment of disease burden,
including periodic reassessments as conditions change and new
assessment tools become available.
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